Skip to main content

   Progress...

Completion of this survey is voluntary and the information collected will only be utilized by BARDA to increase the value of future BARDA Industry Days for you, our customer. For more information on privacy please visit the Privacy Notice (HTML)
.
 

1.  Organization  (required)



2.  Select the answer that most closely reflects your response to each statement below.

Was online registration easy to use?
         
Was onsite registration easy to use?
         
Was the conference location appropriate for the event type?
         
Were area hotels and public transportation useful?
         
Were BARDA staff onsite helpful?
         
Do you plan to attend BARDA Industry Day next year?
         
Did you download the conference app?
         
Was it easy to use?
         
Were the Push Notifications helpful?
         

Day One – Plenary Sessions

3.  Please rate 1 (Low value) to 5 (High value) based on the value of the presentation.

Welcome – Dr. Robert Kadlec, ASPR
1    2    3    4    5
Keynote Speaker – Dr. Steven H. Walker, DARPA
1    2    3    4    5
Leadership Perspective - ADM Brett Giroir, Assistant Secretary for Health
1    2    3    4    5
Partner perspective – Dr. Phil Gomez, SIGA Technologies, Inc.
1    2    3    4    5
Partner perspective - Mr. Gordon Naylor, Seqirus
1    2    3    4    5
Director’s Report – Dr. Rick Bright
1    2    3    4    5
CBRN Threats Program – Dr. Chris Houchens
1    2    3    4    5
IEID Program - Dr. Robert Johnson
1    2    3    4    5
DRIVe – Mr. Tyler Merkeley
1    2    3    4    5
BARDA Contracts, Management And Acquisitions - Mr. S. Kyle Roberts
1    2    3    4    5

Day One – Afternoon Breakout Sessions

4.  Please rate 1 (Low value) to 5 (High value) based on the value of the presentation.

Session 1 2 3 4 5
 

CBRN Programs

  • Vaccines
  • Antitoxins and antivirals
  • Antibacterials
 

DRIVe Innovation: Accelerators

 

Lightning Talks

 

CBRN Programs

  • Radiological and Nuclear MCMs
  • Chemical MCMs
  • Thermal Burns
  • Biodosimetry and other CBRN Diagnostics
 

Addressing AMR: CARB-X and other Models

 

Establishing a Whole of Government Approach to ADM

 

Influenza and Emerging Infectious Disease Programs

  • Vaccine Development
  • Vaccine Stockpile
  • Therapeutics
  • Diagnostics
 

New Approaches to Combating Opioids

 

Project BioShield & the Strategic National Stockpile


Day Two – Plenary Sessions

5.  Please rate 1 (Low value) to 5 (High value) based on the value of the presentation.

Welcome Back – Dr. Rick Bright, BARDA Director
1     2     3     4     5
Keynote Speaker – Dr. Martine Rothblatt, United Therapeutics
1     2     3     4     5
Conversation with - Dr. Robert Kadlec, ASPR
Moderator: Mr. Steve Brozak, WBB Securities
1     2     3     4     5
Venture Capital Perspectives - Panel Discussion
1     2     3     4     5
Featured Speaker - Ms. Melinda Richter, Johnson & Johnson Innovation, JLABS
1     2     3     4     5

Day Two – Afternoon Breakout Sessions

6.  Please rate 1 (Low value) to 5 (High value) based on the value of the presentation.

Session 1 2 3 4 5
 

DRIVe

  • ENACT
  • Solving Sepsis
  • EZ BAA
 

DoD/collaborating on MCM priorities

 

Partnering with BARDA: TechWatch to BAA

 

Perspectives in Pandemic Influenza Preparedness

 

Developing Nonclinical Models with Partners

 

BARDA Public-Private Partnership Case Studies

 

Emergency Use Authorizations for MCMs in an Emergency

 

FDA/Regulatory Considerations for MCM Development

 

Repurposing for Chemical Medical Countermeasures


7.  General Comments and Suggestions:

500 characters left